The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study
17th treatment shown to reduce risk in
March 2021 *, now known with p = 0.0000087 from 27 studies, recognized in 42 countries.
Efficacy is variant dependent.
|
PSM retrospective 1,344 patients in the USA, showing lower hospitalization with monoclonal antibody treatment. Authors combine patients treated with bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab.
This study is excluded in meta
analysis:
results are only provided for use of one or more treatments within a class of treatments, results for each treatment are not provided.
3.
Pochtovyi et al., In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, Vaccines,
doi:10.3390/vaccines11101533.mdpi.com, doi.org.
risk of death, 61.0% higher, RR 1.61, p = 0.40, treatment 1,344, control 1,344, propensity score matching.
|
risk of ICU admission, 51.0% higher, RR 1.51, p = 0.50, treatment 1,344, control 1,344, propensity score matching.
|
risk of hospitalization, 49.0% lower, RR 0.51, p < 0.001, treatment 1,344, control 1,344, propensity score matching.
|
risk of progression, 39.0% lower, RR 0.61, p < 0.001, treatment 1,344, control 1,344, ER visit, propensity score matching.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Nagler et al., 15 Oct 2022, retrospective, USA, peer-reviewed, mean age 59.5, 14 authors, study period 24 November, 2020 - 15 May, 2021.
Contact:
arielle.nagler@nyumc.org.
Abstract: The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective
cohort study
Arielle R. Nagler, MD, The Ronald O. Perelman Department of Dermatology, NYU Grossman
t
us
cr
ip
Leora I. Horwitz, MD, MHS, Department of Medicine and Department of Population Health,
NYU Grossman School of Medicine, New York, NY, USA
Simon Jones, PhD, Department of Population Health, NYU Grossman School of Medicine,
M
an
New York, NY, USA
d
Christopher M. Petrilli, MD, NYU Grossman School of Medicine, New York, NY, USA
ce
York, NY, USA
pt
e
Eduardo Iturrate, MD, Department of Medicine, NYU Grossman School of Medicine, New
Ac
Jennifer L. Lighter, MD, Division of Pediatric Infectious Diseases, Department of Pediatrics,
NYU Grossman School of Medicine, New York, NY, USA
Michael Phillips, MD, Division of Infectious Disease, Department of Medicine, NYU
Grossman School of Medicine, New York, NY, USA
© American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please
e-mail: journals.permissions@oup.com.
School of Medicine, New York, NY, USA
Brian P. Bosworth, MD, Department of Medicine, NYU Grossman School of Medicine, New
York, NY, and NYU Langone Health, New York, NY, USA
Bruce Polsky, MD, Department of Medicine, NYU Long Island School of Medicine, New York,
t
us
cr
ip
Frank M. Volpicelli, MD, Department of Medicine, NYU Grossman School of Medicine, New
York, NY, USA
an
Isaac Dapkins, MD, Family Health Centers at NYU Langone, Brooklyn, NY, USA
M
Anand Viswanathan, MD, Department of Medicine, NYU Grossman School of Medicine,
pt
e
d
New York, NY, USA
Fritz François, MD, Department of Medicine, NYU Grossman School of Medicine, New York,
ce
NY, and NYU Langone Health, New York, NY, USA
Ac
Gary Kalkut, MD, MPH, Division of Infectious Disease, Department of Medicine, NYU
Grossman School of Medicine, New York, NY, and NYU Langone Health, New York, NY, USA
Address correspondence to Dr. Nagler (Arielle.Nagler@nyumc.org).
Twitter: @ArielleNaglerMD
NY, USA
Purpose: Despite progress in the treatment of coronavirus disease 2019 (COVID-19),
including the development of monoclonal antibodies (mAbs), more clinical data to support
the use of mAbs in outpatients with COVID-19 is needed. This study is designed to
determine the impact of bamlanivimab, bamlanivimab/etesevimab, or
t
Methods: A retrospective cohort study was conducted at a single academic medical center
us
cr
ip
with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or
older who tested positive for COVID-19 or were treated with a COVID-19–specific therapy,
including COVID-19 mAb therapies, at the study site between November 24, 2020, and May
15, 2021, were included. The primary outcomes included rates of emergency department
M
from the date of COVID-19 diagnosis.
an
(ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days
Results: A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients
d
with COVID-19 patients who were not treated with mAb therapy. Within 30 days of
pt
e
diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED
and 79 (5.9%) were admitted...
nagler
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit